Loading stock…

Alamar Biosciences, Inc. (ALMR) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Alamar Biosciences, Inc.

ALMRMarket cap $1.93BPrice $27.8

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Makes ultra-sensitive protein detection systems that catch disease biomarkers at concentrations thousands of times fainter than standard lab tools can see. Its NULISA platform lets researchers spot early signs of cancer, neurodegeneration, and other diseases before symptoms even appear.

In Bastion Portfolios?

52W Return+3%

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)+60%10

Rev CAGR (3y)+45%10

Rev CAGR (5y)+41%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-41%1

Net Income Margin-49%1

Free Cash Flow Margin-68%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-16%1

ROAna–

Earnings Stability44

GEAR+VERY WEAK9

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV6.23

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-3.6%2

Dividend Yieldna–

Momentum

Short term

1 month return-7%4

3 month return+10%8

YTD return+26%8

Mid term

Price vs 52wHigh70%3

1 year return+26%8

Long term

3 year return+26%4

5 year return+26%5

Risk Shield

Price Risk

Betana–

Volatility84%1

Free Cash Flow

Free Cash Flow Margin-68%1

Free Cash Flow Yield-3.6%2

Quality

ROCE-22%1

Earnings Stability44

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

ALMRAlamar Biosciences

Revenue FY25$74M

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+60%10

Revenue, next 3Y, CAGR+45%10

Revenue, next 5Y, CAGR+41%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue is set to grow 45%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 45%/yr from here.

The runway holds up: revenue is set to grow 41%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE45 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return+10%8

YTD return+26%8

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return+26%8

3-year return+26%4

5-year return+26%5

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+10%) and so far this year (+26%).

WATCH

Average long-term results. Multi-year returns are middling (+26% over three years and +26% over five), roughly average for the market.

It's up 26% over the past year, but 30% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-7%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Alamar Biosciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ALMRAlamar Biosciences

Revenue FY25$74M

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+60%10

Revenue, next 3Y, CAGR+45%10

Revenue, next 5Y, CAGR+41%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue is set to grow 45%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 45%/yr from here.

The runway holds up: revenue is set to grow 41%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE45 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return+10%8

YTD return+26%8

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return+26%8

3-year return+26%4

5-year return+26%5

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+10%) and so far this year (+26%).

WATCH

Average long-term results. Multi-year returns are middling (+26% over three years and +26% over five), roughly average for the market.

It's up 26% over the past year, but 30% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-7%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Alamar Biosciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community